Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2025 Earnings Presentation
18 slides from Alkem Laboratories's earnings presentation, Feb 7, 2025
Slide 1: Investor Presentation Q3 & 9MFY25
Investor Presentation Q3 & 9MFY25 February 07, 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q3FY25
Key Highlights of Q3FY25 • Total Revenue from Operations was ₹ 33,743 million, with YoY growth of 1.5%. o India sales were ₹ 23,649 million, with YoY growth of 5.9%. o The contribution of domestic sales to total sales in Q3FY25 was 71.1% vs. 68.6% in Q3FY24. o International sales were ₹ 9,605 millio
Slide 4: Key Financial Highlights – Q3FY25 (Consolidated)
Key Financial Highlights – Q3FY25 (Consolidated) All figures in ₹ Mn Total Revenue from Operations Domestic sales 23,649 22,328 33,239 33,743 Q3FY24 Q3FY25 International sales 10,240 9,605 Q3FY24 Q3FY25 Q3FY24 Q3FY25
Slide 5: Key Financial Highlights – Q3FY25 (Consolidated)
Key Financial Highlights – Q3FY25 (Consolidated) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 7,076 7,594 20,193 21,700 60.8% 64.3% 21.3% 22.5% Q3FY24 Q3FY25 Q3FY24 Q3FY25 PBT (before exceptional item) PAT (after Minority Interest) 5,950 6,258 7,062 7,311 17.9% 18.5% Q3
Slide 6: India - Secondary Sales Performance
India - Secondary Sales Performance Mixed performance across all major therapeutic segments in Q3FY25 1 3 3 2 8 Market rank Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Gynaec Acute Therapies 12.2% 9.3% 7.4% 6.9% 7.5% 5.0% 5.4% 2.0% 2.1% 2.8% Alkem sales growth Y
Slide 7: US Business Update
US Business Update Q3FY25 Sales of ₹ 6,340 million (7.3% YoY de-growth) • Overall contribution of US sales to total sales was 19.1% in Q3FY25. • During the quarter, the Company has received two approvals from the USFDA, including one tentative approval. Q3FY25 – US Sales (₹ Mn) Q3FY25 – US Sales (₹
Slide 8: Other International Market Update
Other International Market Update Q3FY25 Sales of ₹ 3,265 million (4.0% YoY de-growth) • Other International Market sales contributed 9.8% to total sales in Q3FY25. • The Company has a presence mainly in Latin America, Australia and Europe. Q3FY25 – Other International Sales (₹ Mn) Q3FY25 – Other In
Slide 9: Key Highlights of 9MFY25
Key Highlights of 9MFY25 • Total Revenue from Operations was ₹ 98,208 million, with YoY growth of 0.9%. o India sales were ₹ 68,482 million, YoY growth of 6.0%. o The contribution of domestic sales to total sales in 9MFY25 was 70.6% vs. 67.6% in 9MFY24. o International sales were ₹ 28,463 million, w
Slide 10: Key Financial Highlights – 9MFY25 (Consolidated)
Key Financial Highlights – 9MFY25 (Consolidated) All figures in ₹ Mn Total Revenue from Operations Domestic sales 64,613 68,482 97,318 98,208 9MFY24 9MFY25 International sales 30,928 28,463 9MFY24 9MFY25 9MFY24 9MFY25
Slide 11: Key Financial Highlights – 9MFY25 (Consolidated)
Key Financial Highlights – 9MFY25 (Consolidated) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 21,209 59,016 63,358 18,435 60.6% 64.5% 18.9% 21.6% 9MFY24 9MFY25 9MFY24 9MFY25 PBT (before exceptional item) PAT (after Minority Interest) 18,596 15,022 21,307 17,648 15.4% 18
Slide 12: India - Secondary Sales Performance
India - Secondary Sales Performance Mixed performance across all major therapeutic segments in 9MFY25 1 3 3 2 8 Market rank Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Gynaec Acute Therapies 12.6% 10.6% 9.6% 7.5% 7.9% 2.5% 5.2% 6.0% 5.3% 3.3% Alkem sales growth
Slide 13: US Business Update
US Business Update 9MFY25 Sales of ₹ 18,732 million (12.7% YoY de-growth) • Overall contribution of US sales to total sales was 19.3% in 9MFY25. • As of December 31, 2024, the Company had filed 179 ANDAs and 2 new drug applications (NDAs) with the USFDA. Of these, it had received approvals for 154 A
Slide 14: Update on USFDA inspections as of Dec 2024
Update on USFDA inspections as of 31 Dec 24 Facility Capability Inspection Date Regulatory Status Baddi (India) Formulations Mar-24 EIR Received in June 2024 Daman (India) Formulations Aug-19 EIR Received in Oct 2019 Taloja R&D (India) Bioequivalence Centre Oct-22 No observation Ankleshwar (India) A
Slide 15: Other International Market Update
Other International Market Update 9MFY25 Sales of ₹ 9,731 million (2.9% YoY growth) • Other International Market sales contributed 10.0% to total sales in 9MFY25. • The Company has a presence mainly in Latin America, Australia and Europe. 9MFY25 – Other International Sales (₹ Mn) 9,459 9,731 9MFY24
Slide 16: Shareholding Pattern as on Dec 31, 2024
Shareholding Pattern as on Dec 31, 2024 Non-Institution BSE Ticker 539523 16.12% NSE Symbol ALKEM Promoter & Shares Outstanding (Mn) 120 Promoter Group MCap (Rs in Mn)* 673,868 Institution 55.66% 28.22% Free Float Mcap (Rs in Mn) 298,861 Industry Pharmaceuticals *Share Price - Rs 5,636 from NSE as o
Slide 17: Key Financial Highlights – Q3 & 9MFY25 (Consolidated)
Key Financial Highlights – Q3 & 9MFY25 (Consolidated) All figures in ₹ Mn Particulars Q3FY25 Q3FY24 YoY growth 9MFY25 9MFY24 YoY growth Revenue from Operations 33,743 33,239 1.5% 98,208 97,318 0.9% Gross Profit 21,700 20,193 7.5% 63,358 59,016 7.4% Gross Profit Margin 64.3% 60.8% 64.5% 60.6% EBITDA
Slide 18: Thank You
Thank You For any queries, contact: Purvi Shah Head of Investor Relations Mobile: +91 84337 00890 E-mail: purvi.shah@alkem.com Tel: +91 22 3982 9999 Ext: 9447